Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

Melissa Cambron, Jop Mostert, Marie D'Hooghe, Guy Nagels, Barbara Willkens, Jan Debruyne, Luc Algoed, Winn Verhagen, Raymond Hupperts, Dorothea Heersema, Jacques De Keyser*, Liesbeth De Groot, Erwin Foselle, Daniel Guillaume, Henri Merckx, Ludo Vanopdenbosch, Mathieu Vokaer, Nina De Klippel, Dirk Nuytten, Ann Van RemoortelAnoek Symons, Miguel D'haeseleer, Veronique Bissay, Annick Van Merhaegen-Wieleman, Michel Van Lint, Veronique Michiels, Patrick Haentjens, Bart Van Wijmeersch, Bart Tillemans, Wim Van Hecke, Gerald Hengstman, FLUOX-PMS Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1728-1735
Number of pages8
JournalMultiple Sclerosis Journal
Volume25
Issue number13
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Multiple sclerosis
  • progressive multiple sclerosis
  • clinical trial
  • fluoxetine
  • outcome
  • neuroprotection
  • EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
  • DOUBLE-BLIND

Cite this